ELAGOLIX SODIUM is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for endometriosis.
ELAGOLIX SODIUM is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for endometriosis.
Genitourinary
| US DMF |
sodium;4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoate